US judge hearing fight over Amgen deal for Horizon eyes September trial
CHICAGO (Reuters) – The judge who will decide if Amgen can go forward with its $27.8 billion purchase of Horizon Therapeutics on Tuesday said he was considering an evidentiary hearing on the…
Amgen says experimental obesity drug has promising durability
By Deena Beasley LOS ANGELES (Reuters) – Amgen Inc’s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company…
Amgen says Lumakras cuts risk of lung cancer progression by 34%
By Deena Beasley (Reuters) – Amgen Inc’s Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company…
Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
By Michael Erman NEW YORK – The U.S. Senate Finance Committee is widening its investigation into the tax practices of U.S. drugmakers to include Amgen Inc, according to a letter sent on…
Amgen drug extends survival in some inoperable colon cancers
By Nancy Lapid (Reuters) – The following are summaries of some of the cancer research advances being presented the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Amgen…
Breaking News
